NCT06286657

Brief Summary

The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2023

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

January 17, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 29, 2024

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

April 15, 2025

Status Verified

April 1, 2025

Enrollment Period

2.3 years

First QC Date

January 17, 2024

Last Update Submit

April 10, 2025

Conditions

Infection Viral

Outcome Measures

Primary Outcomes (1)

  • Changes in severity and duration of viral infections

    Changes in score of Wisconsin Upper Respiratory Symptom Survey

    90 days

Secondary Outcomes (2)

  • Changes in blood lipid levels

    90 days

  • Changes in cognitive skills

    90 days

Study Arms (2)

Intervention

EXPERIMENTAL

Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days

Dietary Supplement: Xanthohumol

Placebo

EXPERIMENTAL

Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days

Dietary Supplement: Placebo

Interventions

XanthohumolDIETARY_SUPPLEMENT

Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days

Intervention
PlaceboDIETARY_SUPPLEMENT

Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days

Placebo

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • healthy
  • BMI \>18 kg/m² or \< 28kg/m²

You may not qualify if:

  • food intolerances
  • food allergies
  • chronic inflammatory diseases
  • metabolic diseases
  • intake of immunosuppressive medication
  • severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months
  • influenza infection in the "current" flu season

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Vienna

Vienna, 1090, Austria

RECRUITING

MeSH Terms

Conditions

Virus Diseases

Interventions

xanthohumol

Condition Hierarchy (Ancestors)

Infections

Central Study Contacts

Ina Bergheim, Prof. Dr.

CONTACT

+43-1-4277-54981ina.bergheim@univie.ac.at

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Dr. Ina Bergheim

Study Record Dates

First Submitted

January 17, 2024

First Posted

February 29, 2024

Study Start

August 1, 2023

Primary Completion

October 31, 2025

Study Completion

December 30, 2025

Last Updated

April 15, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations

AU(1)